Gilead Prices Remdesivir At $2,340 In Developed Nations

Gilead Prices Remdesivir At $2,340 In Developed Nations

Gilead Sciences Inc on June 29 priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations. The vaccine is expected to be in high demand as one of the only treatments so far shown to alter the course of COVID-19. Watch the video to know more
https://www.moneycontrol.com/news/world/gilead-prices-covid-19-drug-remdesivir-at-2340-per-patient-in-developed-nations-5478371.html

Follow us:
Website: https://www.moneycontrol.com/
Facebook: https://www.facebook.com/moneycontrol/
Twitter: http://www.twitter.com/moneycontrolcom
Instagram: https://www.instagram.com/moneycontrolcom/

#moneycontrol
cached video